Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Low-density lipoprotein cholesterol (LDL-C) level
研究概览
简要总结
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain.
This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
- •(Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease
排除标准
- •Inability to provide valid consent by the patient or his legal guardian
- •Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.
- •Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy < 6 months.
结局指标
主要结局
Low-density lipoprotein cholesterol (LDL-C) level
时间窗: Week 52
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52
次要结局
- Modification of lipid lowering therapy (LLT)(Week 52)
- Tolerability of Lipid Lowering Therapy(Week 52)
- Rate of subject meeting LDL-C target(Week 26)
- 12-Item Short Form Survey (SF-12)(Week 52)
- Rate of major adverse cardiovascular event (MACE)(Week52)
- Lipid Lowering Therapy adherence(Week 52)
研究者
GuangMing Tan
Clinical Assistant Professor
Chinese University of Hong Kong